No-deal Brexit could deepen Europe's shortage of medicines: experts

File: The app allows people to look up medicine prices.

File: The app allows people to look up medicine prices.


BRUSSELS - As the deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit.

Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

Pharmaceutical companies have expressed similar concerns about medicines, and some have reserved air freight capacity to fly in supplies if needed.

READ: Brexit turmoil drives UK economy towards recession

But the impact on medical supplies will also be felt beyond Britain. About 45 million packs of medicines are shipped from Britain to the rest of the bloc every month, in trade worth nearly 12 billion pounds in 2016, according to a British parliament report.

Some drugs might not have the required regulatory approval by then to continue being brought in from Britain. About 1 billion packs go in one direction or the other each year, industry data show.

READ: No-deal Brexit to cause food shortages: lobby group

Increased customs controls at ports and other borders between Britain and the EU could also disrupt supplies of drugs and the chemical compounds needed to produce them, regulators and industry representatives say.

"Despite intensive preparation by industry for every scenario, a no-deal Brexit risks disruption to the supply of medicines" throughout the EU, Andy Powrie-Smith, an official at the European Federation of Pharmaceutical Industries and Associations, told Reuters.

The EU drugs regulator, the European Medicines Agency (EMA), said the bloc is well prepared for Brexit and has finalised authorisations for nearly all the 400 drugs under its watch that required further clearing because of Britain's impending departure.

READ: EU unveils 10-point blueprint for post-Brexit future

But authorisation is pending for three medicines that need EU-wide licences, an EMA official said without identifying them.

Other essential medicines could also be blocked because of supervisory hurdles because of Brexit, EMA data show.

The agency is the only body that can authorise sales in the 28-country EU of new drugs to treat the most common and serious diseases, including cancer, diabetes and flu.